Reta Face: What Fast Weight Loss on Retatrutide Does to Your Face

Reta face (also searched as "reta peptide face") is what users call the hollow cheeks, sunken eyes and looser skin some people notice after losing weight fast on retatrutide. It's the same look that got called "Ozempic face" on semaglutide, and as far as anyone can show, it comes from facial fat shrinking along with body fat. No retatrutide trial has measured the face. What's known comes from studies of other weight loss drugs and bariatric surgery, plus what users report.

As of October 2026, retatrutide is still in Phase 3 trials, and no approved version exists yet (see FDA approval and the release date page). The reason the face comes up so often is the size of the weight loss: in TRIUMPH-1, people on 12 mg lost 28.3% of their body weight on average over 80 weeks (efficacy estimand; the NEJM paper's primary analysis, which counts everyone randomized, gives 25.0%).

What is reta face?

A 2026 paper in the Aesthetic Surgery Journal lists sunken cheeks, hollow eyes, sagging skin and an aged look as what rapid weight loss on anti-obesity drugs can do to a face. It isn't a medical diagnosis, and none of the 33 retatrutide studies listed on ClinicalTrials.gov measures the face, skin or appearance, going by our search of every record's title and outcome measures on October 31, 2026.

The name borrows from what doctors already see with semaglutide and tirzepatide. In a 2026 Dermatologic Surgery survey of 406 doctors, nurses and physician assistants, midface volume loss and loose skin on the face and neck topped the list of changes they linked to GLP-1 drugs.

Reddit has its own threads on it, from people worried about a gaunt face and people hoping to lose face fat. Those are individual reports, not a study, and we couldn't verify any single thread, so we don't quote them.

Does retatrutide burn face fat?

Yes, in the sense that it shrinks fat everywhere and the face is part of everywhere. What it can't do is aim fat loss at your face or steer it away. The only published retatrutide whole-body scan we found, a substudy of the Phase 2 type 2 diabetes trial published in The Lancet Diabetes & Endocrinology in 2025, found total fat mass fell 23.2% on 12 mg over 36 weeks, against 4.5% on placebo. The authors, all Lilly employees, wrote that the share of weight lost as lean tissue was similar to other obesity treatments (more in muscle loss on retatrutide). The published abstract doesn't break out the face.

The face follows the scale, so start with the size of the loss. Across TRIUMPH-1's three doses, average weight loss climbed with dose, and the top dose took off 70.3 lb (31.9 kg) on average over 80 weeks. The one measure of body shape Lilly reported was the waist, down 24.1 cm (9.5 in) on 12 mg against 3.6 cm on placebo, which the belly fat page covers.

One researcher has argued, in a 2025 Journal of Cosmetic Dermatology review, that GLP-1 drugs may shrink facial fat faster than body fat through a local effect in the fat itself. The author works for a private company, and nobody has tested the idea in people on retatrutide.

If you want a leaner face and don't have much weight to lose, there's no data for you. Lilly's Phase 2 obesity trial, reported in the New England Journal of Medicine, enrolled people with a BMI of 30 or more, or 27 or more with a weight-related condition. The nearest hint is TRIUMPH-4, where 18.2% on 12 mg stopped because of side effects against 4.0% on placebo. Lilly said those stops tracked baseline BMI and included people who felt they were losing too much weight.

How much weight loss shows in the face?

The best-known number comes from a 2009 study of 186 pairs of identical twins in Plastic and Reconstructive Surgery. A panel judged each twin's age from photos. In twins under 40, the one with a BMI 4 points higher looked older. Past 40, the heavier twin looked younger. With an 8-point BMI gap, the switch came at 55.

That's a comparison between twins, not a weight loss study, but it gives a scale to measure retatrutide against. TRIUMPH-1's average starting BMI was 40.0, and the last two columns are our arithmetic from Lilly's average weight changes (efficacy estimand).

Every retatrutide dose moved the average BMI further than the 4-point gap in the twins study, and 9 mg and 12 mg went past the 8-point gap too. In the 104-week extension of 532 people with a starting BMI of 35 or more, the group that started on 12 mg reached a 30.3% loss (efficacy estimand, at a maximum tolerated dose of 9 or 12 mg) from an average BMI of 42.8, about 13 points on our math.

People with type 2 diabetes lose less. In TRANSCEND-T2D-2, the first head-to-head trial, Lilly reported these 80-week averages from a starting BMI of 36.8 (efficacy estimand only; the BMI columns are our math):

The Ozempic arm lost about 3.5 BMI points, just under the twins' 4-point gap. Retatrutide took off roughly twice that, and nobody compared the faces. To work out your own number, multiply your starting BMI by the percent lost: a BMI of 35 and a 20% loss is 7 points. Our read: if you're past 40 and on track for a TRIUMPH-sized loss, plan on your face looking different, maybe older, even while your other health numbers improve. The weight loss calculator puts the trial averages against your own starting weight, and retatrutide vs Ozempic covers the rest of that trial.

What studies of fast weight loss found about the face

None of these studies gave anyone retatrutide. They're the nearest evidence there is, and they measure different things: judged age, doctors' impressions, patients' worries and surgery records.

Bigger total losses and older age went with more facial aging in the bariatric cohort, which fits the twins data. The preprint found weight loss without GLP-1 drugs wasn't linked to more eyelid surgery (hazard ratio 1.31, not statistically significant). It's one unreviewed database study of women with diabetes and high blood pressure, so treat it as a lead.

Why the face changes the way it does

Your face has separate pads of fat under the skin, some near the surface and some deeper, all sitting on bone. A 2026 review in Dermatologic Surgery describes medical weight loss changing several of these layers at once: the surface fat pads deflate, deep support is lost, bone is slowly resorbed and the skin gets looser. Midface volume loss seems to happen mainly in the surface pads, according to the review, which flattens the cheek's contour and makes the borders between areas of the face easier to see.

Age decides how that reads, as the twins and bariatric studies above show. The eyelid preprint's authors single out the upper eyelid because its skin is thin with very little fat beneath it. We couldn't find any study that measured whether facial skin tightens again after weight loss on a GLP-1 drug.

Two other changes get blamed on reta face. Hair thinning is one: on Zepbound, 5% of people on 5 mg had hair loss against 1% on placebo, and 7.1% of women against 0.5% of men. That's tirzepatide data, not retatrutide, and no retatrutide release has reported a hair loss rate. The other is a burning or oversensitive feeling in the skin (dysesthesia), which affected 12.5% of people on 12 mg in TRIUMPH-1 against 0.9% on placebo. It changes how skin feels, and the side effects hub covers both.

What may soften reta face

Nothing has been tested to prevent it on retatrutide, so everything here is borrowed evidence.

• Protect your skin from the sun and don't smoke. In the twins study, years of smoking and more sun exposure both went with an older-looking face, and a history of not using sunscreen did too.
• Talk to your doctor about where you want to end up. In the bariatric cohort, people who lost the largest share of their excess weight showed the most facial aging, and the twins data suggests a little more weight flatters an older face.
• Eat enough and keep your strength up. No retatrutide trial has tested a diet or exercise plan for this, but the authors of the 1,226-person survey suggest attention to nutrition and strength alongside weight loss drugs, since appearance worries can make people give up on treatment.
• Ask a dermatologist or facial plastic surgeon about fillers or collagen-stimulating injections once your weight is steady. In the Dermatologic Surgery survey, hyaluronic acid filler was the top-rated option for the face.

Pace is the open question. Trials start at 2 mg and step up every 4 weeks, according to Lilly's TRIUMPH-1 release, and nobody has tested whether a slower climb spares the face. The 1,226-person survey didn't record speed of loss, so it can't answer it either. The weight loss timeline shows how fast the trial averages came off. Lilly's October 2026 FAQ warns that illicit products may have too much or too little active ingredient, or the wrong one. In a September 14, 2026 safety advisory, Australia's TGA said a vial sold as retatrutide held no retatrutide at all, only undeclared semaglutide at about 8 times the level in approved products. If you're weighing retatrutide for sale online, you're also guessing at the dose, and in the trials the dose set how fast weight came off.

Nobody knows whether stopping undoes it. In the Phase 2 fatty liver substudy published in Nature Medicine, some weight came back within 4 weeks of the last dose, and nobody has checked where that fat goes. The stopping retatrutide page covers regain, and retatrutide before and after covers progress photos you can compare month to month.

When face changes need a doctor

Most reta face is cosmetic. A few face changes aren't.

A drawn, dry face with dizziness and very little urine after days of vomiting or diarrhea points to dehydration rather than fat loss. The tirzepatide label ties most reported kidney injury on that drug to that kind of fluid loss, so get checked rather than waiting it out. Tell the doctor what you injected and where it came from.